share_log

Pfizer | 10-Q: Q3 2024 Earnings Report

Pfizer | 10-Q: Q3 2024 Earnings Report

輝瑞 | 10-Q:2024財年三季報
美股SEC公告 ·  11/05 05:10

牛牛AI助理已提取核心訊息

Pfizer Inc. reported a significant increase in total revenues for the third quarter of 2024, with a 31% rise to $17.7 billion compared to $13.5 billion in the same period of 2023. This growth was primarily driven by the performance of Paxlovid, revenues from legacy Seagen products, and the Vyndaqel family. Excluding Paxlovid and Comirnaty, revenues still saw a 14% operational increase. Income from continuing operations before taxes saw a dramatic turnaround from a loss of $3.4 billion in Q3 2023 to a profit of $4.7 billion in Q3 2024. Pfizer's business development initiatives remain focused on advancing their product pipeline and maximizing the value of existing products, with strategic priorities including achieving oncology leadership and delivering pipeline innovation. Looking ahead, Pfizer plans to enhance shareholder value through capital allocation, cost realignment, and technology investments, including artificial intelligence. The company also launched a Manufacturing Optimization Program expected to deliver savings by 2027. Despite global economic challenges and the ongoing COVID-19 pandemic, Pfizer anticipates strong operating cash flows and the ability to meet liquidity needs, supporting ongoing operations and strategic initiatives.
Pfizer Inc. reported a significant increase in total revenues for the third quarter of 2024, with a 31% rise to $17.7 billion compared to $13.5 billion in the same period of 2023. This growth was primarily driven by the performance of Paxlovid, revenues from legacy Seagen products, and the Vyndaqel family. Excluding Paxlovid and Comirnaty, revenues still saw a 14% operational increase. Income from continuing operations before taxes saw a dramatic turnaround from a loss of $3.4 billion in Q3 2023 to a profit of $4.7 billion in Q3 2024. Pfizer's business development initiatives remain focused on advancing their product pipeline and maximizing the value of existing products, with strategic priorities including achieving oncology leadership and delivering pipeline innovation. Looking ahead, Pfizer plans to enhance shareholder value through capital allocation, cost realignment, and technology investments, including artificial intelligence. The company also launched a Manufacturing Optimization Program expected to deliver savings by 2027. Despite global economic challenges and the ongoing COVID-19 pandemic, Pfizer anticipates strong operating cash flows and the ability to meet liquidity needs, supporting ongoing operations and strategic initiatives.
輝瑞公司報告,2024年第三季度總收入顯著增長,較2023年同期增長31% 至177億美元,而2023年同期爲135億美元。這一增長主要得益於Paxlovid的表現、傳統Seagen產品的收入以及Vyndaqel系列。不包括Paxlovid和Comirnaty,收入仍然實現了14%的營運增長。稅前持續經營收入從2023年第三季度的34億美元虧損大幅轉爲2024年第三季度的47億美元盈利。 輝瑞的業務發展重點仍然是推進其產品管線並最大化現有產品的價值,戰略重點包括實現腫瘤學領先地位和推出管線創新。展望未來,輝瑞計劃通過資本配置、成本重新調整和技術投資(包括人工智能)來增強股東價值。該公司還推出了一個預計到2027年將實現節省的製造業優化計劃。儘管全球經濟面臨挑戰,新冠疫情仍在持續,但輝瑞預計將獲得強勁的經營現金流,並有能力滿足流動性需求,支持持續業務和戰略舉措。
輝瑞公司報告,2024年第三季度總收入顯著增長,較2023年同期增長31% 至177億美元,而2023年同期爲135億美元。這一增長主要得益於Paxlovid的表現、傳統Seagen產品的收入以及Vyndaqel系列。不包括Paxlovid和Comirnaty,收入仍然實現了14%的營運增長。稅前持續經營收入從2023年第三季度的34億美元虧損大幅轉爲2024年第三季度的47億美元盈利。 輝瑞的業務發展重點仍然是推進其產品管線並最大化現有產品的價值,戰略重點包括實現腫瘤學領先地位和推出管線創新。展望未來,輝瑞計劃通過資本配置、成本重新調整和技術投資(包括人工智能)來增強股東價值。該公司還推出了一個預計到2027年將實現節省的製造業優化計劃。儘管全球經濟面臨挑戰,新冠疫情仍在持續,但輝瑞預計將獲得強勁的經營現金流,並有能力滿足流動性需求,支持持續業務和戰略舉措。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。